Keith Kaye, MD, MPH, on the Approval of Imipenem/Cilastatin + Relebactam
imipenem/cilastatin plus relebactam was approved for the treatment of cUTIs and cIAIs in adult patients with limited or no available treatment options.
Yoav Golan, MD, on the Recent Approval of Ceftolozane/Tazobactam for HABP/VABP
This approval allows ceftolozane/tazobactam to be used to treat hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP).
The Year Ends With a Big Step in PrEP and PEP
Something novel in infectious diseases practice has occurred and, like many big changes, it is not without controversy.
Robert F. Poirier, Jr. MD, on the Approval of Lefamulin for CABP
In August, the FDA approved lefamulin (Xenleta) for the treatment of CABP after results from 2 phase 3 studies showed that the novel antibiotic was noninferior to existing treatment options.
Karam Mounzer, MD, on the Approval of Dolutegravir/Lamivudine
In April, the US Food and Drug Administration (FDA) approved dolutegravir plus lamivudine as a complete 2-drug regimen for treatment naïve adults with HIV-1.
Two More Agents Bolster the Arsenal Against Gram-Negative Resistance
As the antibiotic pipeline produces new therapies, clinicians must understand each agent’s specific role in manage­ment of patients infected by multidrug-resistant pathogens.
An Unknown Contagious Rash: Case Report and Literature Review of Norwegian Crusted Scabies
A patient with HIV and skin lesions should trigger a broad differential.
What's on Your Antimicrobial Stewardship "Wish List"?
If resources and funds were unlimited, what would the ideal stewardship program look like?
Hepatitis A Outbreaks on the Rise in the US
An epidemiologist explores the changing epidemiology of a familiar disease.
Alternative Antiretroviral Medication Delivery Systems Emerge to Treat, Prevent HIV Infection
Novel modes of delivery are imperative to improve HIV suppression and prevent transmission.
Get Off the SOFA! Introducing the Quick Pitt Bacteremia Score
The quick Pitt Bacteremia Score offers accuracy comparable to the original version's across multiple infections, and maintains ease of use.
Teaching Old Dogs New Tricks: Make the Most of Twitter to Boost ID Education, Engagement, and Advocacy
Infectious diseases clinicians turn to Twitter as a tool for education and collaboration.
Differences in C difficile Diagnostics Blunt the Benefits of Bezlotoxumab
Bezlotoxumab, a human monoclonal anti­body directed against Clostridioides diffi­cile toxin B, is currently indicated for the prevention of recurrent C diffi­cile infection
Entering the Ring: Oral Vancomycin Versus Metronidazole for C difficile Infection and the Risk of Vancomycin-Resistant Enterococcus
In 2017, a guideline update stripped metronidazole of its first-line therapy designation and crowned oral vancomycin as initial therapy for all C difficile infection cases.
Antibiotic Prophylaxis Prior to Dental Procedures Largely Unnecessary, Tied to Risks
A total of 168,420 dental visits included antibiotic prophylaxis, 136,177 (80%) of which were deemed unnecessary.
Evaluating Microarray Patches for Long-Acting PrEP and Contraceptives
Microarray patches could be key to providing a self-delivery system, that is also discreet, to administer HIV prevention and contraception to women in low-resource settings.
ACX-362E a Promising Potential Treatment for C difficile, First-in-Human Phase 1 Trial Demonstrates
Investigators observed no moderate, severe, cumulative, or dose-limiting adverse events leading to discontinuation, and ACX-362E was generally well-tolerated at all dose levels.
All-Cause Mortality of Cefiderocol Versus Meropenem in Nosocomial Pneumonia
Investigators assessed rates of all-cause mortality at Day 14 for Cefiderocol and meropenem in patients with nosocomial gram-negative pneumonia.
HIV Treatment Advice for Community Physicians
Experts provide community physicians treating HIV with practical advice for screening, diagnosing, and managing patients with HIV.
2 Commerce Drive Cranbury, NJ 08512